Key result
MDM2 inhibition improves hepatic triglyceride-VLDL secretion and alleviates MAFLD by preventing ApoB degradation.
Why the study?
The association between cardiovascular health measured by Life's Essential 8 and Life's Simple 7 and metabolic-associated fatty liver disease in the United States remains unclear.
Is higher adherence to cardiovascular health criteria (LE8 and LS7) associated with a lower prevalence of metabolic-associated fatty liver disease in the US population?
Is higher adherence to cardiovascular health criteria (LE8 and LS7) associated with a lower prevalence of metabolic-associated fatty liver disease in the US population?
Higher adherence to cardiovascular health metrics (Life's Essential 8 and Life's Simple 7) is associated with a significantly lower risk of metabolic-associated fatty liver disease.
Supports MDM2 inhibition as a potential MAFLD target; hypothesis-generating and should not yet change practice.
BACKGROUND: Cardiovascular health (CVH) plays a crucial role in overall health, but its association with metabolic-associated fatty liver disease (MAFLD) remains unclear. AIM: To investigate the relationship between CVH, measured using Life's Essential 8 (LE8) and Life's Simple 7 (LS7), and the prevalence of MAFLD. METHODS: This cross-sectional study had a sample of 2234 individuals, representing approximately 120 million individuals in the United States. Baseline parameters were compared between the LE8 and LS7 groups. Logistic regression models were used to evaluate the relationship between LE8, LS7, and MAFLD, while taking into account confounding factors. The investigation employed restricted cubic splines to investigate non-linear associations. Subgroup analyses and sensitivity studies were performed to evaluate the strength and reliability of the results. RESULTS: Higher LE8 and LS7 scores were significantly associated with a decreased risk of MAFLD, even after controlling for demographic, socioeconomic, and clinical variables. This association demonstrated a non-linear pattern, with the most dramatic risk reduction observed at higher CVH levels. Individual CVH components, notably healthy behaviors and factors, exhibited strong relationships with MAFLD. Subgroup analyses indicated consistent relationships across several demographics. Sensitivity tests utilizing other MAFLD definitions validated the robustness of the findings. CONCLUSION: Higher adherence to CVH criteria, as indicated by LE8 and LS7 scores, is associated with a significantly lower risk of MAFLD. These results emphasize the need to advance CVH to control and avoid MAFLD.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2025) studied Metabolic Associated Fatty Liver Disease (n=76). Hepatic MDM2 deletion or inhibition vs. Wild-type littermates or vehicle control was evaluated on ApoB degradation and Triglyceride-VLDL secretion. Hepatic MDM2 promotes metabolic-associated fatty liver disease by blocking triglyceride-VLDL secretion via ApoB degradation, an effect alleviated by MDM2 deficiency or pharmacological inhibition.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: